Neurocrine Biosciences, Inc. · NASDAQ:NBIX
Neurocrine Biosciences — Investor Presentation (May 2009)
68 slides from Neurocrine Biosciences's investor presentation, May 18, 2009
Slide 1: A Pipeline of Innovation
A Pipeline of Website Presentation 5/18/09
Slide 2: Forward-looking statements and risks
This presentation includes early and late stage clinical data and projections based thereon that involve a number of risks and uncertainties. These risks include the specific risk that the clinical development of the products discussed will not successfully proceed to later stage clinical trials or
Slide 3: Pipeline
Pipeline Products Indication Preclinical Phase 1 Phase 2 Phase 3 Elagolix Endometriosis Elagolix Benign Prostatic Hyperplasia CRF1 Antagonist Anxiety/Depression (561679) CRF1 Antagonist (586529) Anxiety/Depression CRF2 Agonist (Urocortin 2) Cardiovascular VMAT2 Inhibitor Movement Disorders (NBI-9885
Slide 4: GnRH Program
GnRH Program Orally Available, Nonpeptide Antagonists A Pipeline of Website Presentation 5/18/09
Slide 5: GnRH: Central Regulator of Reproductive Endocrine System
GnRH: Central Regulator of Reproductive Endocrine System Hypothalamic‐Pituitary‐Gonadal Axis Estrogen Dose‐Response Hierarchy Hypothalamus —100 —Synthesis of Liver GnRH Proteins —Optic —(TBG, CBG, SHBG) Conccentration reequired for E2 effect n pg/mL —Chiasma —80 —Posterior —Pituitary Concentration —
Slide 6: U.S. Endometriosis Market
U.S. Endometriosis Market Large, clinically significant patient base Many women of child …and symptoms are primarily bearing age have perceived as moderate or endometriosis… severe by those diagnosed… 8 7.5MM 7 23% 6 5 Milllions 4 3 2 1 77% 0 N = 62,481 Prevalence in Mild Moderate/Severe generall po
Slide 7: Endometriosis Treatment Options
Endometriosis Treatment Options Option Issues Wait for menopause It could be a while… NSAIDS (e.g. advil) Insufficient pain relief Oral Contraceptives (OCPs) Insufficient pain relief May help get pregnant, but Laparascopic ablation typically recurs Hysterectomy/remove H ste ectom / emo e oovaries a
Slide 8: Clinical Trials as of May 2009
Clinical Trials as of May 2009 Phase Description Study Number Total Subjects Subjects On Elagolix Ph 1 SD / MD, female NBI‐56418‐0301 55 45 Ph 1 Site absorption, male NBI‐56418‐0401 6 6 Ph 1 SD, male NBI‐56418‐0402 8 8 Ph 1 Formulation relative PK, Formulation, PK male NBI 56418 0404 NBI‐56418‐0404
Slide 9: NBI-56418-0702 Top-line Results
NBI-56418-0702 Top-line Results M h 2009 March A Pipeline of Website Presentation 5/18/09
Slide 10: Lilac Petal Study NBI-56418-0702
Lilac Petal Study NBI-56418-0702 A Pipeline of Website Presentation 5/18/09
Slide 11: Mean Baseline Characteristics
Mean Baseline Characteristics Subjects Randomized After Placebo Lead-In (ITT population N=154) Placebo Elagolix 150 mg Elagolix 250 mg N=52 N=51 N=51 Age (years) 31.2 30.9 31.0 Dysmenorrhea D h Monthly CPSSS (0-3) 2.3 2.4 2.5 Daily eDiary Mean(0-3) 1.2 1.4 1.3 Non-Menstrual Pelvic Pain Monthly CPSSS
Slide 12: Efficacy Endpoints: Elagolix vs. Placebo
Efficacy Endpoints: Elagolix vs. Placebo Top-line Results, Results ITT Population Placebo 150 mg 250 mg Change From Baseline to Week 12 N=52 N=51 N=51 Numeric Rating Scale (mean daily pain, 0-10) -0.90 -1.19 -1.25 Numeric Rating Scale (peak pain, 0-10) -1.33 -2.45* -2.75** Non-Menstrual Pelvic Pain
Slide 13: Moderate or Severe Non-Menstrual Pelvic Pain Subset Analyses
“Moderate” or “Severe” Non-Menstrual Pelvic Pain at Baseline Subset Exploratory Analyses 150 mg 250 mg Efficacy Endpoint N=32 N=32 Numeric Rating Scale (mean daily pain, pain 00-10) 10) p=0 0436 p=0.0436 p=0 0688 p=0.0688 Numeric Rating Scale (peak pain, 0-10) p=0.0356 p=0.0775 Total Score ((DYS + N
Slide 14: Subjects Reporting Treatment-Emergent AEs
Subjects Reporting Treatment-Emergent AEs From Randomization to Week 12 Adverse Event Placebo Elagolix 150 mg Elagolix 250 mg N=52 N=51 N=52 n (%) n (%) n (%) Headache 1 (1.9) 5 (9.8) 4 (7.7) Vaginal Mycoses 2 (3.8) 0 (0.0) 3 (5.8) Acne 1 (1 (1.9) 9) 0 (0 (0.0) 0) 3 (5 (5.8) 8) Nausea 1 (1.9) 6 (11.
Slide 15: Subject Disposition at Week 12
Subject Disposition at Week 12 Preliminary Status, Reconciliation Pending (Safety Population N=155) Discontinuation Placebo Elagolix 150 mg Elagolix 250 mg Reason N=52 N=51 N=52 n (%) n (%) n (%) Adverse Event 0 (0.0) 1 (2.0) 1 (1.9)* Protocol Deviation 0 (0.0) 0 (0.0) 0 (0.0) p Non-Compliance 0 ((0
Slide 16: Summary and Conclusions
Summary and Conclusions Statistically significant and clinically meaningful improvements with elagolix in patients with endometriosis confirmed. Elagolix 150 mg and 250 mg demonstrate statistical superiority to placebo Dysmenorrhea, y , Dyspareunia, y p , peak p NRS,, EHP-5 (p (pain)) and PGIC. Aver
Slide 17: NBI-56418-0603 Top-line Results After 6-Month Treatment
NBI 56418 0603 NBI-56418-0603 Top-line Results After 6-Month Treatment September 2008 A Pipeline of Website Presentation 5/18/09
Slide 18: Petal Study Design
Petal Study Design A Pipeline of Website Presentation 5/18/09
Slide 19: Study Successful at Primary Endpoint Week 24
Study Successful at Primary Endpoint Week 24 LS Mean and 95% Confidence Interval A Pipeline of 19 Website Presentation 5/18/09
Slide 20: Confirmation of Bone Safety at Week 24 and Week 48
Confirmation of Bone Safety at Week 24 and Week 48 LS Mean and 95% Confidence Interval for Elagolix 150 mg qd A Pipeline of 20 Website Presentation 5/18/09
Slide 21: Confirmation of Bone Safety at Week 24 and Week 48
Confirmation of Bone Safety at Week 24 and Week 48 LS Mean and 95% Confidence Interval for Elagolix 75 mg bid A Pipeline of 21 Website Presentation 5/18/09
Slide 22: Positive Control (DMPA) at Week 24 and Week 48
Positive Control (DMPA) at Week 24 and Week 48 LS Mean and 95% Confidence f Interval A Pipeline of 22 Website Presentation 5/18/09
Slide 23: N-Telopeptide Biomarker Confirms Minimal Bone Effects
N‐Telopeptide Biomarker Confirms Minimal Bone Effects Week 12 and 24 (Treatment) and Week 48 (Post Treatment) —Mean (SD) values shown, normal range 6‐19 nM BCE for this age group. A Pipeline of 23 Website Presentation 5/18/09
Slide 24: Elagolix Effects on Bone Compare Favorably
Elagolix Effects on Bone Compare Favorably Women 20‐45 yyears off age g Duration of Change in Spine Treatment or Treatment/Condition Reference BMD Observation b i (months) Healthy females with ‐1.1% 12 Waller et al, 1999 irregular g menses Oral Contraceptives in Conflicting data, see Teergarden 0 to
Slide 25: Clinically Meaningful and Statistically Significant Change from Baseline
Clinically Meaningful and Statistically Significant Change from Baseline Secondary endpoints p<0.0001 LS Mean* Score Reduction at Month 6 Mean Score Elagolix Elagolix DMPA-SC Efficacy Assessment at Baseline 150 mg qd 75 mg bid 104 mg n=252 n=54 n=63 n=48 CPSSS Total 9.1 -5.5 -5.2 -5.3 Dysmenorrhea 2
Slide 26: Significant Improvement in Total CPSSS
Significant Improvement in Total CPSSS Mean±SEM Change From Baseline) (M A Pipeline of Website Presentation 5/18/09
Slide 27: Total CPSSS: ITT Population
Total CPSSS: ITT Population Mean Score by Study Week —Week 24 —Week 48 —P<0.0001 —P<0.0001 A Pipeline of 27 Website Presentation 5/18/09
Slide 28: Total CPSSS: Completers
Total CPSSS: Completers Mean Score by Study Week —Week 24 —Week 48 —P<0.0001 —P<0.0001 A Pipeline of 28 Website Presentation 5/18/09
Slide 29: Dysmenorrhea
Dysmenorrhea Mean Score by Study Week —Week 24 —Week 48 —P<0.0001 —P<0.0001 A Pipeline of 29 Website Presentation 5/18/09
Slide 30: Responders: Dysmenorrhea
Responders: Dysmenorrhea Improvement of ≥1 point During Treatment A Pipeline of 30 Website Presentation 5/18/09
Slide 31: Non-Menstrual Pelvic Pain
Non‐Menstrual Pelvic Pain Mean Score by Study Week —Week 24 —Week 48 —P<0.0001 —P<0.0001 A Pipeline of 31 Website Presentation 5/18/09
Slide 32: Responders: Non-Menstrual Pain
Responders: Non‐Menstrual Pain Improvement of ≥1 point During Treatment A Pipeline of 32 Website Presentation 5/18/09
Slide 33: Endometriosis Health Profile (EHP-5)
Endometriosis Health Profile (EHP‐5) Never Rarely Some‐ Often Always Dimension Question times P i Pain FFound d it difficult diffi lt to t walk lk because of the pain? Control and Powerlessness g symptoms Felt as though y p are ruling your life? Emotional Well Being Had mood swings? Social Support F
Slide 34: Improvement In EHP-5 Core Dimensions
Improvement In EHP‐5 Core Dimensions Subject % Reporting Impact of Endometriosis Symptoms “N “Never”” or “R l ” IInterfering “Rarely” f i with i h Lif Life 90 80 70 60 50 40 30 20 10 0 Pain Control Well‐being Well being Social Self Image Support Baseline Month 6 Month 12 —Example for subjects random
Slide 35: Individual vs. Group Median Estradiol
Individual vs. Group Median Estradiol —E2 for an individual subject j —Median E2 for a g group p of unsynchronized y reflects a specific Cycle Day. subjects will reflect a cross‐section of Cycle Days. A Pipeline of 35 Website Presentation 5/18/09
Slide 36: Median Estradiol Trends by Treatment
Median Estradiol Trends by Treatment Elagolix g Maintains E2 Near Baseline Levels 100 —At baseline —After 1st month, untreated subjects no longer subjects are synchronized; Estradiol median for group approximately 80 synchronized: pg/ml 80 Cycle Day 2‐5, Mediian Estradiol Value E2 at nadir 60 —Targe
Slide 37: Median Estradiol and Spine BMD at Month 6
Median Estradiol and Spine BMD at Month 6 Modeling of relationship from Petal Study confirms Barbieri hypothesis of estrogen threshold All subjects pooled; change in BMD from All Subjects: Baseline BMD ‐0.7% Median estradiol threshold predicts E2 ≤ 11.8 11.8 <E2<72.5 E2 > 72.5 change in BMD from BMD
Slide 38: Reduction in Vaginal Bleeding
Reduction in Vaginal Bleeding Mean (SD)% of Days With Any Bleeding 60 Screening — Reduction in vaginal g Treatment bleeding reflects 50 pharmacological effect of 40 treatments — DMPA is associated with 30 amenorrhea and 20 persistent spotting — Elagolix is associated with 10 decrease in menses or 0
Slide 39: Evidence of Ovulation Post Treatment
Evidence of Ovulation Post Treatment More Rapid p Following g Elagolix g Discontinuation —Last dose A Pipeline of 39 Website Presentation 5/18/09
Slide 40: Reasons for Discontinuation During Treatment
Reasons for Discontinuation During Treatment Reason for Elagolix 150 mg qd Elagolix 75 mg bid DMPA‐SC Total Discontinuation n=84 n=84 n=84 n=252 n (%) n (%) n (%) n (%) Adverse event* 4 (4.8) 6 (7.1) 13 (15.5) 23 (9.1) Protocol deviation 2 (2.4) 0 (0) 0 (0) 2 (0.8) Non‐compliance Non compliance 1 (1
Slide 41: Treatment-Emergent AEs: During Treatment
Treatment‐Emergent AEs: During Treatment Adverse Event >10% Elagolix 150 mg qd Elagolix 75 mg bid DMPA‐SC n(%) n(%) n(%) Headache 18 ((21.4%)) 22 ((26.2%)) 13 ((15.5%)) Nausea 14 (16.7%) 11 (13.1%) 12 (14.3%) Pharyngolaryngeal pain 7 (8.3%) 5 (6.0%) 3 (3.6%) Upper respiratory infection 7 (8.3%) 7 (8
Slide 42: Hot Flashes
Hot Flashes Comparable rate of hot flashes during 1 month of screening and 6 months th off treatment t t t Elagolix 150 mg Elagolix 75 mg Period/Statistic DMPA SC qd bid During Screening n=84 n=84 n=84 Mean #/day (SD) 0.25 (0.45) 0.32 (1.1) 0.29 (0.79) Median #/day 0.00 0.00 0.00 During Treatment n=
Slide 43: Petal Study Successful
Petal Study Successful Pain reduction without bone loss ¾ Primary endpoint met – Lower bound of 95%CI did not exceed -2.2% change from baseline for either spine or femur bone mineral density – Data support selection of once daily dosing in 702 and 703 trials ¾ Secondary endpoints met – Significant r
Slide 44: Clinical Development 2009
Clinical Development 2009 Elagolix Study Phase Output Timing 0702 DXA assessment; 6 months PhIIb Dose confirmation in treatment; standard labs; efficacy Placebo Portion endometriosis d t i i (150mg (150 qd d + 250 • data d t ((summer 2009) Complete mg qd) 0703 As with 0702 plus active comparator Com
Slide 45: 703 Trial in Central Eastern Europe
703 Trial in Central Eastern Europe Currently Randomizing, n=180 (target) A Pipeline of Website Presentation 5/18/09
Slide 46: Endometriosis Market Research
Endometriosis Market Research A Pipeline of Website Presentation 5/18/09
Slide 47: Pharmacological Treatments: Significant Off-label Use
Pharmacological Treatments Significant Off-label Use (Physicians) Q18: Which pharmacological treatments have you prescribed or recommended for your Endometriosis patients? Indicated for Endometriosis Off-label 94.0% 97 0% 97.0% 97.0% NBIX primary market research, n=100 physicians A Pipeline of Websi
Slide 48: General Perceptions: Oral Products Preferred
General Perceptions Oral Products Preferred Physicians Patients NBIX primary market research, n=104 patients, n=100 physicians A Pipeline of Website Presentation 5/18/09
Slide 49: Contraceptive TRx (Volume)/Market Size
Contraceptive TRx (Volume)/Market Size Off-label Use (US) – Intent to Use (2009) Combined Ob/Gyn and PCP Prescribing Habits Off-label Use – Intent to Use TRx >15 MM/yr NBIX primary market research, n=100 Physicians, IMS Health 2008 A Pipeline of Website Presentation 5/18/09
Slide 50: New Treatment Option Product X
New Treatment Option Product X Q93: Assume that a NEW prescription medication (“PRODUCT X”) were to be introduced to the market for the treatment of endometriosis. The medication would be a once daily tablet that acted in a dose dependent fashion to suppress hormones important to endometriosis. The
Slide 51: Treatment of Mild-Severe Endometriosis Product X
Treatment of Mild-Severe Endometriosis Product X Q94-96: For the treatment of “Mild” Mild – “Severe” Endometriosis please indicate what percent (%) each Severe Endometriosis, pharmacological class of therapeutic below would contribute to your total first-line therapy. Mild Moderate Severe NBIX prima
Slide 52: Multiple Markets - Multiple Compounds
Multiple Markets - Multiple Compounds Women’s Health Men’s Health Gynecology Gynecology Oncology Urology • Endometriosis •Uterine Fibroids • Breast Cancer • Benign Prostatic • Prostate P t t Cancer C H Hypertrophy t h (BPH) First Second Third Elagolix “Phase 2b” Primary Indications Back-Up p “Develo
Slide 53: Elagolix Intellectual Property
Elagolix Intellectual Property 5 Issued U.S. Patents covering: – elagolix composition of matter – pharmaceutical composition – methods of using g elagolix g Last composition of matter patent expires 2024 (not including patent term extension) Corresponding Foreign Applications pending or issued (expi
Slide 54: Elagolix Publications / Planning Ongoing
Elagolix Publications / Planning Ongoing Greater than 50 Publications US Obstetrics and Gynecology – Volume 3 Issue 1 2008 A Pipeline of Website Presentation 5/18/09
Slide 55: Recent Elagolix Publications
Recent Elagolix Publications Greater than 50 Publications — Abstracts in 2009 — ESHRE Methodology June — Endo09 Bone data June — ASRM Efficacy/Safety October A Pipeline of Website Presentation 5/18/09
Slide 56: CRF Receptor Antagonists
CRF Receptor Antagonists A Pipeline of Website Presentation 5/18/09
Slide 57: CRF Antagonists: Current Status of NBI / GSK Compounds
CRF Antagonists Current Status of NBI / GSK Compounds 2006 2007 2008 2009 Compound 561679 Phase I Phase II PoC Novel chemotype and Studies Depression pharmacologic profile Multi-dose study complete Started mid 2008 Depression Phase I Compound 586529 IBS Studies O Ongoing i A Pipeline of Website Pres
Slide 58: Urocortin 2 for Congestive Heart Failure
Urocortin 2 for Urocortin 2 Congestive Congestive Heart Failure ((CHF)) Heart Failure ((CHF)) A Pipeline of Website Presentation 5/18/09
Slide 59: Urocortin 2 Summary of Results to Date
Urocortin 2 Summary of Results to Date Urocortin 2 represents a First in Class opportunity for the treatment of acutely y decompensated p heart failure ((ADHF)) – Novel mechanism of action – Multiple physiological actions Intravenous t a e ous infusion us o of o Urocortin U oco t 2 in stable stab e
Slide 60: VMAT2 Inhibitor Program
Urocortin 2 for VMAT2 Congestive Inhibitor Program Heart Failure ( (CHF) ) A Pipeline of Website Presentation 5/18/09
Slide 61: VMAT2 Target for Hyperkinetic Movement Disorders
VMAT2 Target for Hyperkinetic Movement Disorders VMAT2 inhibition validated mechanism for symptom reduction of chorea, tardive dyskinesia, tics and other hyperkinetic movement disorders. disorders Kenney and Jankovic, 2006 The only approved medication targeting VMAT2 has pharmacologic and pharmacoki
Slide 62: Optimal PK and Safety Profile
Optimal PK and Safety Profile Hum an m ean C H CxTTPProfile fil off NBI-98854 NBI 98854 and d NBI NBI-98782 98782 Follow ing Single Oral Adm inistration of NBI-98854 @ 25m g or NBI-98782 @ 19 m g 70 • Improved safety expected based upon: NBI-98854 dosed @ 25mg 60 NBI-98782 from NBI-98854 @ 25mg ng/m
Slide 63: VMAT2 Inhibitor Program – Tardive Dyskinesia
VMAT2 Inhibitor Program – Tardive Dyskinesia (Ready for Phase I start) Advanced Development Preclinical Lead Candidate Development Phase 1 Phase 2 Phase 3 (Q4 ‘07) (Q1 ‘08) (Q4 ‘08) (Q2 ‘09) NBI 98854 NBI‐98854 • Chemical class established efficacy • Neurocrine’s Clinical Candidate – Tardive dyskine
Slide 64: R&D Capabilities
Urocortin 2 for R&D Congestive Capabilities p Heart Failure ((CHF)) A Pipeline of Website Presentation 5/18/09
Slide 65: Neurocrine Capabilities: R & D
Neurocrine Capabilities: R & D Discovery Research Preclinical Development Advanced Programs Early Novel Discovery Approaches Preclinical Chemical Pharmaceutical DMPK & Safety Development Development Discovery Phase III Research with CRO / Partner Phase I/II Conducted by NBI Clinical Programs For Spe
Slide 66: Research Technology
Research Technology Real Time Data Integration in Drug Discovery ¾ Automated Drug Discovery Processes – Chemical synthesis, Purification, Analytical, Focused Libraries – SAR of Primary Assays Assays, hERG hERG, CYP Inhibition ¾ Pharmacology Know-how and Insights - SiNERG – Receptor Kinetics / Recept
Slide 67: Research Targets
Research Targets ¾ Drug discovery platform which integrates the fundamental principles perfected in GPCR pharmacology (kinetics, efficacy, and desensitization) to drive novel target drug discovery / SAR process. – Neurology (Pain, Epilepsy, Movement Disorders) – Metabolic disorders (Diabetes) – Psyc
Slide 68: Financial Highlights
Financial Highlights Year Ending Quarter Ending December 31, 31 2008 March 31 31, 2009 Revenues and $ 2.7 million $ 0.7 million other income Operating and other $ 91.3 million $ 20.4 million Expenses Net loss $ (88.6) million $ (19.7) million Cash and Investments $ 101.5 million $ 86.0 million A Pip
Neurocrine Biosciences — Investor Presentation (May 2009) on 6ix